Thromboembolic Disease After Knee Arthroplasty is Rare in Southern Iran

Overview

Journal J Orthop

Specialty Orthopedics

Date 2015 May 15

PMID 25972699

Authors

G Hossain Shahcheraghi

Mahzad Javid

Mohammad M Arasteh

Affiliations

Soon will be listed here.

Abstract

Background: Thromboembolic disease (TED) after knee arthroplasty occurs infrequently in Iran. The aim of this study was to examine the incidence of TED in patients with osteoarthritis undergoing knee replacement in Southern Iran while on prophylaxis.

Materials & Methods: In a case series study from January to December 2012, 100 consecutive total knee arthroplasty (TKA) candidates were evaluated for TED by clinical evaluation and Doppler sonography preoperatively and 2 months postoperatively and by clinical evaluation one year after surgery. The patients in this study randomly received either warfarin or enoxaparin prophylactically.

Results: A total of 77 women and 23 men with mean age of 67 years (52-82 years) entered the study. The average hemoglobin drop of 2.7 g with warfarin and 3.3 with enoxaparin was observed. No case of TED, pulmonary embolus (PE), major bleeding, post-thrombotic syndrome, or hemarthrosis was observed.

Conclusion: No clinically significant DVT was found using either enoxaparin or warfarin prophylaxis after TKA in Southern Iran. Relatively excessive postoperative bleeding was observed, particularly with enoxaparin.

References

Sudo A, Sano T, Horikawa K, Yamakawa T, Shi D, Uchida A . The incidence of deep vein thrombosis after hip and knee arthroplasties in Japanese patients: a prospective study. J Orthop Surg (Hong Kong). 2003; 11(2):174-7. DOI: 10.1177/230949900301100212. View

Bauer K, Eriksson B, Lassen M, Turpie A . Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2002; 345(18):1305-10. DOI: 10.1056/NEJMoa011099. View

Galat D, McGovern S, Hanssen A, Larson D, Harrington J, Clarke H . Early return to surgery for evacuation of a postoperative hematoma after primary total knee arthroplasty. J Bone Joint Surg Am. 2008; 90(11):2331-6. DOI: 10.2106/JBJS.G.01370. View

Lieberman J . American College of Chest Physicians evidence-based guidelines for venous thromboembolic prophylaxis: the guideline wars are over. J Am Acad Orthop Surg. 2012; 20(6):333-5. DOI: 10.5435/JAAOS-20-06-333. View

Fitzgerald Jr R, Spiro T, Trowbridge A, Gardiner Jr G, Whitsett T, OConnell M . Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am. 2001; 83(6):900-6. View

Shaieb M, Watson B, ATKINSON R . Bleeding complications with enoxaparin for deep venous thrombosis prophylaxis. J Arthroplasty. 1999; 14(4):432-8. DOI: 10.1016/s0883-5403(99)90098-0. View

Freedman K, Brookenthal K, Fitzgerald Jr R, Williams S, Lonner J . A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. 2000; 82-A(7):929-38. DOI: 10.2106/00004623-200007000-00004. View

Sachs R, Smith J, Kuney M, Paxton L . Does anticoagulation do more harm than good?: A comparison of patients treated without prophylaxis and patients treated with low-dose warfarin after total knee arthroplasty. J Arthroplasty. 2003; 18(4):389-95. DOI: 10.1016/s0883-5403(03)00071-8. View

Planes A, Vochelle N, Darmon J, Fagola M, Bellaud M, Huet Y . Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996; 348(9022):224-8. DOI: 10.1016/s0140-6736(96)01453-5. View

10.

Colwell C . The ACCP guidelines for thromboprophylaxis in total hip and knee arthroplasty. Orthopedics. 2010; 32(12 Suppl):67-73. DOI: 10.3928/01477447-20091103-51. View

11.

Brookenthal K, Freedman K, Lotke P, Fitzgerald R, Lonner J . A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty. 2001; 16(3):293-300. DOI: 10.1054/arth.2001.21499. View

12.

Cordell-Smith J, Williams S, Harper W, Gregg P . Lower limb arthroplasty complicated by deep venous thrombosis. Prevalence and subjective outcome. J Bone Joint Surg Br. 2004; 86(1):99-101. View

13.

Colwell Jr C, Berkowitz S, Lieberman J, Comp P, Ginsberg J, Paiement G . Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2005; 87(10):2169-77. DOI: 10.2106/JBJS.D.02184. View

14.

Lieberman J, Geerts W . Prevention of venous thromboembolism after total hip and knee arthroplasty. J Bone Joint Surg Am. 1994; 76(8):1239-50. DOI: 10.2106/00004623-199408000-00015. View

15.

Nicolaides A, Breddin H, Fareed J, Goldhaber S, Haas S, Hull R . Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol. 2001; 20(1):1-37. View

16.

Stein P, Kayali F, Olson R, Milford C . Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med. 2004; 116(7):435-42. DOI: 10.1016/j.amjmed.2003.11.020. View

17.

Geerts W, Bergqvist D, Pineo G, Heit J, Samama C, Lassen M . Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):381S-453S. DOI: 10.1378/chest.08-0656. View

18.

Vives M, Hozack W, Sharkey P, Moriarty L, SOKOLOFF B, Rothman R . Fixed minidose versus-adjusted low-dose warfarin after total joint arthroplasty: a randomized prospective study. J Arthroplasty. 2001; 16(8):1030-7. DOI: 10.1054/arth.2001.27688. View

19.

Eriksson B, Dahl O, Buller H, Hettiarachchi R, Rosencher N, Bravo M . A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005; 3(1):103-11. DOI: 10.1111/j.1538-7836.2004.01100.x. View

20.

Perzborn E, Kubitza D, Misselwitz F . Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Hamostaseologie. 2007; 27(4):282-9. View